Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
AgeneBio Featured at Longevity Innovations and Neurodegeneration Company Showcase
HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101
AgeneBio Presents at Biotech Showcase
HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101
Presentation at Alzheimer’s Association International Conference (AAIC) Read more
Darryle Schoepp, Ph.D. joins the AgeneBio Board of Directors
AgeneBio, Inc. panel participation at American College of Neuropsychopharmacology meeting (ACNP)
Bridging the Gap From Research Discovery to a Bonafide Neurotherapeutic: Sponsored by NIH Blueprint Neurotherapeutic Program
Sharon Rosenzweig-Lipson, AgeneBio VP of R&D. presents at Clinical Trials in Alzheimer’s Disease conference (CTAD)
Founder & CEO Dr. Michela Gallagher Featured in Alzheimer’s Drug Discovery Foundation Video
Learn more about our important work in this video.
AgeneBio using over $3M in new funding to further develop Alzheimer’s drug
The Baltimore Business Journal covered our funding for Alzheimer's drug development.
AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions
AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM), a novel approach to mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) that targets hippocampal overactivity that leads to degeneration and cognitive decline in patients with MCI due to AD, autism and schizophrenia.
